Parkinson’s Protein LRRK2 Activity Unveiled, Guiding New Therapies
Researchers at Weill Cornell Medicine have mapped the structural changes of the Parkinson's protein LRRK2, revealing how mutations lead to hyperactivity. This breakthrough guides the development of targeted therapies.